Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierantonio Menna

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Leukemia|December 2, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|October 2, 2025
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|November 3, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
JACC. Cardiooncology|May 2, 2022
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational ApproachGiorgio Minotti, Giorgio Reggiardo, Massimiliano Camilli, et al.
European Cardiology|October 20, 2025
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?Roberta Esposito, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2017
Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol MetabolitesEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Advances in Pharmacology (San Diego, Calif.)|June 6, 2022
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncologyGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Cardio-Oncology (London, England)|December 9, 2020
In ®Entresto we trustMassimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna, et al.
Cardiovascular Toxicology|May 7, 2014
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradoxFabio Cacciapaglia, Emanuela Salvatorelli, Giorgio Minotti, et al.
Chemotherapy|November 11, 2022
Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac DeathGiuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Leukemia|December 2, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|October 2, 2025
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
Leukemia|November 3, 2025
Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinibAlessandra Tedeschi, Anna Maria Frustaci, Pierantonio Menna, et al.
JACC. Cardiooncology|May 2, 2022
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational ApproachGiorgio Minotti, Giorgio Reggiardo, Massimiliano Camilli, et al.
European Cardiology|October 20, 2025
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind?Roberta Esposito, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2017
Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol MetabolitesEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Advances in Pharmacology (San Diego, Calif.)|June 6, 2022
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncologyGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Cardio-Oncology (London, England)|December 9, 2020
In ®Entresto we trustMassimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna, et al.
Cardiovascular Toxicology|May 7, 2014
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradoxFabio Cacciapaglia, Emanuela Salvatorelli, Giorgio Minotti, et al.
Chemotherapy|November 11, 2022
Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac DeathGiuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, et al.
Pageof 7